U.S. markets closed
  • S&P Futures

    4,219.00
    +9.00 (+0.21%)
     
  • Dow Futures

    33,342.00
    +82.00 (+0.25%)
     
  • Nasdaq Futures

    13,431.25
    +39.25 (+0.29%)
     
  • Russell 2000 Futures

    1,974.10
    +4.60 (+0.23%)
     
  • Crude Oil

    91.69
    -0.24 (-0.26%)
     
  • Gold

    1,800.20
    -13.50 (-0.74%)
     
  • Silver

    20.44
    -0.30 (-1.46%)
     
  • EUR/USD

    1.0286
    -0.0016 (-0.15%)
     
  • 10-Yr Bond

    2.7860
    -0.0110 (-0.39%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2187
    -0.0031 (-0.25%)
     
  • USD/JPY

    133.2300
    +0.3570 (+0.27%)
     
  • BTC-USD

    24,275.37
    +1,351.32 (+5.89%)
     
  • CMC Crypto 200

    572.66
    +41.44 (+7.80%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Why Shares of Guardant Health Dropped 33.6% in May

·2 min read
Why Shares of Guardant Health Dropped 33.6% in May
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

It's a bit early for investors to jump the ship regarding Guardant because the biotech stock still has plenty of good long-term prospects. The test will compete with the Galleri blood-based cancer screening by the Grail unit of Illumina and a the Cologuard fecal screening by Exact Sciences. Investors are also watching the outcome of a lawsuit, filed in March by Illumina, that claims that Guardant and two of its founders -- former employees of Illumina -- used Illumina's propriety information to help them launch Guardant.